NCT03541902View on ClinicalTrials.gov

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 15, 2018

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Malignant Neoplasms of Urinary TractRenal Cell CarcinomaChromophobe Renal Cell CarcinomaMetastatic Renal Cell CarcinomaPapillary Renal Cell CarcinomaRenal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene FusionsSarcomatoid Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v8Unclassified Renal Cell Carcinoma
Interventions
DRUG

Cabozantinib

Given PO

DRUG

Sunitinib Malate

Given PO

Trial Locations (3)

77030

M D Anderson Cancer Center, Houston

77094

MD Anderson Regional Care Center-Katy, Houston

77478

MD Anderson Regional Care Center-Sugar Land, Sugar Land

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER